Viewing nowCombinationDucanova Tablet 60/5 mg (Fimasartan, Esamlodipine)
Fimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 7.48mg
Tablet · Prescription medication · Combination
Daewoong Bio Co., Ltd.

MFDS item code 202300096 · Approved 2023.01.06 · Insurance code 694003940
Treatment of essential hypertension not controlled with fimasartan monotherapy
This medication is used to assist in effective blood pressure control in patients with essential hypertension who are not adequately controlled on Fimasartan Potassium monotherapy.
The recommended dose of this medicine is 1 tablet once daily, taken with water, with or without food. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). It is recommended that the dose be adjusted using fimasartan before starting this medicine; however, if blood pressure is not controlled as described below, switching directly to this medicine may be considered. ㆍ 30/2.5 milligrams: Administer to patients whose blood pressure is not adequately controlled with fimasartan 30 milligrams as monotherapy. ㆍ 60/2.5 milligrams: Administer to patients whose blood pressure is not adequately controlled with fimasartan 60 milligrams as monotherapy. ㆍ 60/5 milligrams: Administer to patients whose blood pressure is not adequately controlled with fimasartan 60 milligrams as monotherapy or this medicine 60/2.5 milligrams. Patients taking fimasartan and S-amlodipine (amlodipine) concomitantly may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience. Elderly patients No initial dosage adjustment is necessary for elderly patients 70 years of age or younger. Patients with renal impairment No dosage adjustment is necessary in patients with mild to moderate renal impairment (creatinine clearance 30 ~ 80 mL/min); however, in patients with severe renal impairment (creatinine clearance < 30 mL/min), treatment should be initiated with fimasartan 30 milligrams in this medicine. Patients with hepatic impairment No dosage adjustment is necessary in patients with mild hepatic impairment; however, this medicine should not be administered to patients with moderate to severe hepatic impairment.
The safety and efficacy of this medicine in pediatric and adolescent patients 18 years of age or younger have not been established.
This medication can cause serious harm to the fetus and newborn in the second and third trimesters of pregnancy; it should be discontinued immediately upon confirmation of pregnancy. It is contraindicated in patients with allergies to the active ingredients or similar components, in pregnant or breastfeeding women, in patients undergoing renal dialysis, in patients with severe liver impairment, and in patients with bile duct obstruction. Patients with low blood volume or low salt levels, impaired kidney function, renal artery hypertension, aortic stenosis or mitral stenosis, and the elderly should use this drug with caution and be closely monitored. Side effects such as dizziness, headache, facial or peripheral edema, urinary disturbances, insomnia, and flushing may occur; if symptoms are severe, consult a physician. Hypotension may occur, requiring the patient to lie down and administer fluids if blood pressure drops too low. This medication may increase serum potassium levels; therefore, patients with heart failure or renal disease should regularly check their potassium levels through blood tests. Interactions may occur when used with other antihypertensives, potassium-sparing diuretics, certain anti-inflammatory medications, and lithium. Always inform healthcare providers of other medications being taken. Use during pregnancy carries a risk of serious abnormalities to the fetus, so this medication should be avoided if planning to become pregnant or if currently pregnant. If breastfeeding, it is recommended to discontinue breastfeeding or this medication due to the possibility of excretion into breast milk. Safety in children and adolescents has not been established; it is advised not to use this medication in these populations. Overdose may result in hypotension, cardiac arrhythmias, and severe vasodilation. Care should be taken not to exceed the recommended dosage, and in case of overdose, consult healthcare providers immediately. This medication should be kept out of reach of children, and transferring to another container may compromise quality.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to light; it should be stored in a container that does not allow light. Additionally, it should be stored at room temperature between 1°C and 30°C for safe use.
Orange-colored, rounded square film-coated tablet
30 tablets / bottle, 300 tablets / bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 7.48mg
Tablet · Prescription medication · Combination
Daewoong Bio Co., Ltd.
CombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 7.48mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
NBK Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Ajou Pharmaceuticals Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Kips Biopharma Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Bionex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.